Background: Cystic fibrosis (CF) is the most common autosomal-recessive disorder in western countries. Previous studies have demonstrated an important role of sphingolipids in the pathophysiology of cystic fibrosis. It has been shown that ceramide has a central role in various pulmonary infections, including those with Pseudomonas aeruginosa (P. aeruginosa). Ceramide is accumulated in the airways of CF mice and patients. However, little is known about a potential role of glucosylceramide in cystic fibrosis. Methods: We investigated the expression of glucosylceramide and lactosylceramide in the respiratory tract of murine and human CF samples by immunohistochemistry and analyzed effects of glucosylceramide on P. aeruginosa in vitro. We performed pulmonary infections with P. aeruginosa and tested inhalation with glucosylceramide. Results: We demonstrate that glucosylceramide is down-regulated on the apical surface of bronchial and tracheal epithelial cells in cystic fibrosis mice. Although glucosylceramide did not have a direct bactericidal effect on Pseudomonas aeruginosa in vitro, inhalation of CF mice with glucosylceramide protected these mice from infection with P. aeruginosa, while non-inhaled CF mice developed severe pneumonia. Conclusion: Our data suggest that glucosylceramide acts in vivo in concert with ceramide and sphingosine to determine the pulmonary defense against P. aeruginosa.
Introduction
Cystic fibrosis (CF) is one of the most common autosomal recessive disorders in Western populations, constituting one case per 2,500 births, and is caused by mutations of the cystic fibrosis transmembrane conductance regulator gene (CFTR) [1, 2, 3] . Genetic defects of the CFTR molecule cause several clinical symptoms due to a dysfunctional chloride secretion in epithelial cell layers, which in particular involves pulmonary and gastrointestinal organ surfaces [28] [29] [30] . In higher animals the first sugars linked to ceramide are β-linked galactose (GalCer) or glucose (GlcCer) after which numerous other carbohydrates can be attached [29] .
Despite the fact, that expression of the glycosylsphingolipids GM-1 and asialo-GM-1 is altered in CF respiratory epithelial cells [31, 32] , recent studies revealed that glucosylceramide (GlcCer), one of the simplest glycosphingolipids, may play a role in P. aeruginosa infections [33, 34] . Studies employing miglustat, an inhibitor of two different GlcCer degrading enzymes, glucocerebrosidase (GBA1) and non-lysosomal β-glucosidase 2 (GBA2), showed that this inhibitor reduces levels of ceramide induced by P. aeruginosa infection [33] . It has been demonstrated that GBA1 and GBA2 activities are elevated in CF bronchial cell during P. aeruginosa infection [34] . IL-8 mRNA expression and protein release stimulated by P. aeruginosa in CF bronchial cells were reduced when GBA2 expression and function were decreased [34] . Furthermore, significant ceramide reduction was observed after the addition of the specific inhibitor of GBA2, Genz-529648, in CF bronchial cells infected with P. aeruginosa, which strongly suggests that GBA2 is directly involved in ceramide formation after P. aeruginosa infection [34] .
To gain further insights into the molecular mechanisms of pulmonary P. aeruginosa infections and the role of sphingolipids during infection, we explored the potential involvement of glucosylceramide, alone and combined with sphingosine, in P. aeruginosa infections in CF. The expression of LacCer and GlcCer was examined in respiratory airways of Cftr-deficient mice and the effect of GlcCer in vitro on two different strains of P. aeruginosa was tested. Our studies demonstrate that GlcCer is down-regulated in airway epithelial cells of Cftr-deficient mice. Inhalation of Cftr-deficient mice with GlcCer protected these mice from infection with P. aeruginosa, compared to non-inhaled Cftr-deficient mice. These data indicate an important role of GlcCer in the pulmonary defense against P. aeruginosa.
Materials and Methods

Mice
B6.129P2(CF/3)-Cftr
TgH(neoim)Hgu (abbreviated CF MHH ) congenic mice were used, because they are developing cystic fibrosis in the lungs without manifesting gastrointestinal symptoms due to low expression of Cftr in the intestine [35] . They were generated by brother-sister mating from the original Cftr TgH(neoim) Hgu mutant mouse and then backcrossed into the B6 inbred background. Original Cftr TgH(neoim)Hgu mice were generated by insertional mutagenesis in exon 10 of the Cftr gene [36] . Syngenic B6 mice served as controls. All mice were bred and housed in the special pathogen free facility of the University Hospital, University of Duisburg-Essen, Essen, Germany. Mice were handled according to international guidelines and protocols approved by the Animal Care Committee (Az 84-02.04.2013.A282). To ensure full manifestation of CF disease, mice were used between 14-24 weeks of age.
Human samples
Punch biopsies of human lungs from CF patients and corresponding organ donors were performed at the Department of Thoracic Transplantation, West German Heart and Vascular Center, University Hospital Essen (Germany). Lung biopsies were fixed in 4% paraformaldehyde (PFA) for 36 hrs and then embedded in paraffin.
The study was approved by the local ethics committee, all patients gave informed consent.
Bacteria P. aeruginosa strains 762 and ATCC 27853 were seeded on fresh tryptic soy agar (TSA) plates (Becton Dickinson Biosciences, Heidelberg, Germany) and incubated overnight at 37°C. The next day, bacteria were transferred into 40 mL of pre-warmed, sterile tryptic soy broth (TSB, Becton Dickinson Biosciences) in Erlenmeyer flask. To obtain bacteria in the early logarithmic phase, the optical density at 550 nm was set to 0.225, and bacteria were incubated for 1 h at 37°C on a horizontal shaker (125 rpm). After incubation, bacteria were pelleted by centrifugation (10 min, 1,710xg), resuspended and diluted as indicated below. 3 colony forming units (CFU)/mL. Stock solutions of C16 β-D-glucosylceramide and D-erythro-sphingosine (Avanti Polar Lipids, Inc., Alabama, USA, 860539P and 860490P, respectively) were dissolved in 10% n-octyl-β-D-glucopyranoside (OGP, Sigma-Aldrich, Steinheim, Germany) in a concentration range from 50 µM to 2 mM and bath-sonicated for 10 minutes, if indicated combined and sonicated again. 10 µl of sphingolipids were added to 1 mL bacterial solution and bacteria were incubated for 1 h at 37°C on a horizontal shaker (125 rpm). 200 µL of a bacteria solution were directly plated on LB agar plates, incubated for 14 hrs at 37°C and bacterial CFU were counted.
Infection of mice
For mouse infections studies, P. aeruginosa strain 762 was directly resuspended in pre-warmed HEPES/Saline buffer (H/S, 132 mM NaCl, 20 mM HEPES, 5 mM KCl, 1 mM CaCl 2 , 0.8 mM MgSO 4 , 0.7 mM MgCl 2 , pH 7.4).
Mice were anesthetized for 10-15 seconds with ether and infected by an intranasal injection of 5 x 10 7 CFU in 20 µL H/S. A 30-gauge 1-mL syringe was used to perform nasal injections and the needle was covered with a tightly fitting, smooth plastic tube so that any nasal injuries were avoided. Mice were infected and sacrificed by cervical dislocation 2 hrs after infection. Lungs were immediately removed under sterile conditions, homogenized and lysed in 5 mg/mL saponin for 10 minutes at 37°C to release intracellular bacteria. RPMI-1640 medium (Gibco/Invitrogen, Karlsruhe, Germany) supplemented with 10 mM HEPES was added, samples were centrifuged for 10 minutes at 2,240×g and resuspended in RPMI-1640 medium/10 mM HEPES. Aliquots were plated on TSA plates and after overnight growth bacteria colonies were counted.
Mouse inhalation
Mice were inhaled 45-60 minutes prior to infection using a PARI Boy SX nebulizer (PARI GmbH, Starnberg, Germany) through a mask, which is part of an oral inhalation device for children (LL-Nebulizer) and was clipped at the sides to cover only the nose and the surrounding part of the face. Mice inhaled 800 µL of 0.9% NaCl containing 125 µM C16 β-D-glucosylceramide (Avanti Polar Lipids, Inc., Alabama, USA), that was bath-sonicated 10 minutes directly before use.
Immunostainings
Mice were sacrificed, lungs or trachea instantly removed and fixed for 36 hrs in 4% PFA buffered in PBS.
Mouse and human samples were then dehydrated using increasing (70%-100%) ethanol concentrations and Xylol (PanReac AppliChem), embedded in paraffin, cut in 6 µm thin sections and left in an incubator at 50°C for overnight drying.
Sections were dewaxed using Xylol, and rehydrated by incubation in ethanol with decreasing (100% to 70%) concentrations and Millipore-water. Afterwards, sections were incubated with Pepsin Digest All (Invitrogen Life Technologies, USA) for 30 minutes at 37°C, washed with distilled water, and blocked for 15 minutes with PBS + 0.05% Tween 20 + 5% fetal calf serum (FCS). They were then incubated with polyclonal antibodies directed against glucosylceramide (diluted 1:200, Glycobiotech, Germany, RAS_0010) or lactosylceramide (diluted 1:200, Glycobiotech, Germany, MAS_0090) for 45 minutes. Both antibodies were diluted in H/S plus 1% FCS. Sections were washed three times in PBS plus 0.05% Tween 20, incubated with a Cy3-coupled donkey anti-rabbit IgG (diluted 1:1000, Jackson ImmunoResearch Laboratories, Inc., Pennsylvania, USA, 711-166-152) or a Cy3-coupled donkey anti-mouse IgG (diluted 1:1000, Jackson ImmunoResearch, 715-166-150), washed three times in PBS plus 0.05% Tween 20 and once in PBS, and embedded in Mowiol. Samples were analyzed by confocal microscopy on a Leica TCS SP5 microscope.
Statistics
Data are expressed as mean ± SD. Statistical significance was evaluated using the GraphPad Prism 5 program. Data were analyzed using ANOVA with Bonferroni as post-hoc test for multiple comparisons. A p-value of 0.05 or less was considered significant.
Results
Glycosylsphingolipids in the respiratory tract
Numerous studies have shown that expression of ceramide and sphingosine is altered in the respiratory tract of cystic fibrosis patients and mice and that both sphingolipids have an important role in P. aeruginosa infections [8, 14, 17, 37] . Based on these findings, we aimed to determine if there is a difference in expression of the glycosphingolipids glucosylceramide (GlcCer) and lactosylceramide (LacCer) in the respiratory tract between wild type (WT) and CF mice. Immunohistochemical staining with a glucosylceramide-specific antibody showed higher expression of GlcCer on the apical surface of bronchial and tracheal epithelial cells in wild type mice than in CF mice (Fig. 1A) . There was no difference in expression of LacCer in epithelial cells of the respiratory tract between CF and WT mice (Fig. 1B) . In addition, we analyzed GlcCer expression in human lung samples from CF patients and organ donors. Apical membranes of bronchial cells received from healthy donors showed bright levels for GlcCer, while the staining was much weaker in corresponding areas in CF lungs (Fig. 2A+B ).
These results demonstrate that levels of glucosylceramide are reduced in the respiratory tract of CF patients and mice. 
Glucosylceramide effects on different P. aeruginosa stains
Since levels of sphingosine are also reduced in CF and this sphingolipid acts bactericidal, we hypothesized that GlcCer may also inhibit bacterial growth and that a combination of GlcCer and sphingosine may synergistically impede P. aeruginosa growth.
We tested this hypothesis by incubation of the P. aeruginosa strains 762 and ATCC 27853 in vitro with sphingosine, β-glucosylceramide or their combination in PBS. The results showed that β-GlcCer alone has no significant effect on growth of P. aeruginosa strain ATCC 28753 or 762 (Fig. 3A) . In contrast, sphingosine killed the different P. aeruginosa strains at low micromolar concentrations. However, a combination of sphingosine and GlcCer did not increase the effect of sphingosine (Fig. 3B) . For P. aeruginosa strain 762, the combinations of 10 µM GlcCer with 0.5 µM and 1 µM sphingosine even promoted growth of bacteria when compared to corresponding concentrations of sphingosine alone. Most likely, the bacteria use GlcCer as carbon source and therefore growth is promoted.
These results showed that β-GlcCer and sphingosine do not synergistically inhibit growth of P. aeruginosa in vitro. In fact, at certain ratios of β-GlcCer and sphingosine, β-GlcCer even inhibited the bactericidal effect of sphingosine in vitro.
Inhalation of β-glucosylceramide prevents in vivo infection with P. aeruginosa
To unambiguously analyze the function of GlcCer in the airways of CF mice during infection, we performed in vivo infection experiments. To this end, we inhaled CF mice with β-GlcCer prior to infection with P. aeruginosa 762. Non-inhaled CF and WT mice were also infected with P. aeruginosa and served as controls. Non-inhaled CF mice rapidly succumbed to infection and showed signs of severe pneumonia 2 hrs after intranasal injection of 5 x 10 7 CFU of P. aeruginosa 762, while WT and CF mice inhaled with β-GlcCer showed no or only mild signs of infection by that time. All mice were sacrificed 2 hrs after infection and lungs were removed for analyses of CFU. The short time course allows analyzing the role of β-GlcCer in the acute phase of a pulmonary infection. The results revealed that lungs of β-GlcCer inhaled CF mice contained significantly less bacteria than non-inhaled CF mice (Fig.  4A) . Inhalation of β-GlcCer reduced the infection in CF mice to the low levels in WT mice, which are largely resistant to the infection with P. aeruginosa (Fig. 4A) . To determine if levels of glucosylceramide are altered in the epithelial cells of the lungs after inhalation, we inhaled CF mice with β-GlcCer, sacrificed those 30 min after inhalation, removed the lungs, fixed and embedded them in paraffin. Sections of WT, CF and CF mice inhaled with β-GlcCer were stained with anti-GlcCer antibody. Immunohistochemical stainings showed an increase of GlcCer levels in the apical membranes of bronchial epithelial cells in CF mice after inhalation (Fig. 4B ).
These results demonstrate that inhalation of β-GlcCer in vivo supports the innate immune system to kill P. aeruginosa and, thereby, has a positive effect on survival of CF mice infected with P. aeruginosa strain 762.
Discussion
While the effects of ceramide and sphingosine in P. aeruginosa infections in cystic fibrosis have been well demonstrated [8, 14, 17, 37] , little is known about an effect of glycosphingolipids. Here, we demonstrate that levels of GlcCer are lower on the apical surface of tracheal and bronchial epithelial cells of CF mice than in WT mice. Inhalation of β-GlcCer prevented the development of severe pneumonia in CF mice and allowed the mice to kill the pathogen after intranasal infection of CF mice. This indicates that β-GlcCer contributes to the defense of the airways against P. aeruginosa. In contrast, we did not detect any differences in expression of lactosylceramide in the respiratory tract between CF and WT mice.
It has been shown that sphingosine levels are reduced in epithelial cells of the airways of CF mice and that sphingosine kills P. aeruginosa and S. aureus, but also other pathogens, in vitro and in vivo [17, 37] . Since levels of GlcCer are also reduced in CF, we hypothesised that GlcCer may also act bactericidal in vitro and that a combination of GlcCer and sphingosine may synergistically inhibit P. aeruginosa growth. However, the results showed that GlcCer alone has no significant growth inhibiting effect on both P. aeruginosa strain ATCC 28753 and 762. Furthermore, a combination of sphingosine and GlcCer did not show significantly better inhibition of bacterial growth than sphingosine alone. For the P. aeruginosa strain 762 combinations of 10 µM GlcCer even reduced the bactericidal effect of 0.5 and 1 µM sphingosine. Most likely, the bacteria use GlcCer as carbon source in vitro and therefore growth is promoted. To analyze the function of GlcCer in the airways of CF mice, we performed in vivo experiments and inhaled CF mice with GlcCer prior to infection with P. aeruginosa strain 762. The inhalation of GlcCer greatly promoted elimination of the bacteria from the airways of CF mice and thereby the survival of infected CF mice. At present, it is unknown how GlcCer prevents infection of CF mice with P. aeruginosa. In contrast to sphingosine, GlcCer does not directly kill bacteria. It might be possible that GlcCer interferes with ceramide and in particular ceramide-enriched membrane platforms. Ceramide is greatly increased in CF airways and increased ceramide concentrations were previously linked to the induction of epithelial cell death in CF airways, which in turn results in release of DNA into the airways [8] . DNA in the airways seems to be a critical component of the infection process in CF mice, since we have shown that inhalation with DNase also prevents infection of CF mice with P. aeruginosa [8] . In this scenario, sphingosine provides the normal defense barrier in the upper airways against pathogens. In the absence of sphingosine, as in CF, bacteria reach the lung, but are only able to colonize the lung and induce pneumonia, if further defense mechanisms fail and/or the conditions for growth, such as the presence of free DNA as in CF lungs, are provided. Thus, although not proven, GlcCer may prevent clustering of CD95 in ceramide-enriched membrane domains that has been previously shown to initiate epithelial cell death in CF [22, 38] . By an interference with ceramide-enriched membrane platforms and proteins that cluster within these domains in CF airway epithelial cells, GlcCer might prevent signaling via these platforms and thereby induction of inflammation and cell death. The increase of GlcCer after inhalation would then prove beneficial in CF by preventing these pathologies resulting in the observed protection of CF mice from P. aeruginosa infection.
A beneficial role of GlcCer in CF is also supported by recent findings, which demonstrated that inhibitors of GBA2, the enzyme that degrades GlcCer into ceramide, had a positive effect on the inflammatory response of CF cells induced by P. aeruginosa infection [34] . Inhibition of GBA2 resulted in a concomitant reduction in IL-8 levels and to a significant decrease of the ceramide content in CF bronchial cells infected with P. aeruginosa [34] . Whether levels of GlcCer were also upregulated in epithelial cells upon application of the inhibitor has not been investigated in this study. This and our study indicate an important role of GlcCer in the pulmonary defense against P. aeruginosa. The GBA2 inhibitor miglustat, which was used by Loberto and colleagues [34] , shows good oral bioavailability and is used as drug in Europe and USA [39] . In addition, miglustat can restore the activity of chloride channels in F508del-CFTR respiratory and pancreatic cells [40] . However, a clinical study, recently performed as proof-of-concept study [41] , failed to show a significant change in total chloride secretion assessed by nasal potential difference and sweat chloride values as well as of the forced expiratory volume (FEV1) after 8 days of miglustat administration. Further studies in CF patients are necessary to prove whether miglustat has a beneficial effect on pulmonary infections with P. aeruginosa.
Since GlcCer can be easily administrated via inhalation as an aerosol or as dry substance, our findings hypothesize GlcCer as promising treatment in patients suffering from cystic fibrosis. Given that ceramide also plays a very critical role in cystic fibrosis and normalization of ceramide levels by blockers of the acid sphingomyelinase has been shown to prevent infection and inflammation in cystic fibrosis patients [42] [43] [44] , we hypothesize that a therapy that combines normalization of ceramide levels with inhalation of glucosylceramide and/ or sphingosine [17, 37] might be the most promising way preventing or treating existing bacterial infection in CF patients in the future. Since other drugs, like antibiotics, can also be applied via an inhalation therapy in CF [45] , this way of application offers the benefits of a local administration with minimal adverse systemic effects. It has to be proved if administration of GBA2 inhibitors can also be applied via inhalation and if a combination therapy of ceramide reducing and GlcCer stabilizing/generating strategy is more promising than application of one drug alone.
In summary, we demonstrate that GlcCer is downregulated on the apical surface of bronchial and tracheal epithelial cells in CF mice. Inhalation of CF mice with GlcCer protected Imbalance between sphingolipids ceramide (increased) on the one hand and sphingosine and glucosylceramide (decreased) on the other hand contributes to the high susceptibility of CF mice and patients to bacterial pulmonary infections. Inhalation of C16-glucosylceramide corrects this hypersusceptibility to P. aeruginosa of CF mice.
